TY - JOUR
T1 - Association between Endothelin-1 Levels and Kidney Disease among Blacks
AU - Rebholz, Casey M.
AU - Harman, Jane L.
AU - Grams, Morgan E.
AU - Correa, Adolfo
AU - Shimbo, Daichi
AU - Coresh, Josef
AU - Young, Bessie A.
N1 - Funding Information:
C.M.R. is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K01 DK107782. B.A.Y. is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant R01 DK102134 and the Veterans Affairs Puget Sound Health Care System. The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, and HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities,withadditionalsupportfromtheNationalInstituteonBiomedical Imaging and Bioengineering.
Publisher Copyright:
© 2017 by the American Society of Nephrology.
PY - 2017/11
Y1 - 2017/11
N2 - Endothelin-1, a marker of endothelial dysfunction, is a potent vasoconstrictor released by endothelial cells and an important regulator of renal physiology. It is not known whether elevated serum levels of endothelin- 1 indicate future risk of kidney disease in the general population. In participants in the JacksonHeart Study, a community-based observational study of cardiovascular risk in black adults, we measured serum endothelin-1 level at baseline (2000-2004; n=3538). We defined incident CKD as EGFR,60 ml/min per 1.73 m2 and $30% EGFR decline at the third visit (2009-2013) relative to baseline among those participants with baseline EGFR $60 ml/min per 1.73 m2. At baseline, mean age was 55 years old, 37% of participants were men, and mean EGFR was 94 ml/min per 1.73 m2. Over a median follow-up of 8 years, 228 (6.4%) cases of incident CKD occurred in participants. Participants with baseline endothelin-1 levels in higher quartiles had a greater incidence ofCKDin the fully adjustedmodel (odds ratio for fourth versus first quartile, 1.81; 95% confidence interval, 1.11 to 2.96; Ptrend=0.04). Endothelin-1 positively associated with all-cause mortality (hazard ratio for fourth versus first quartile, 1.64; 95% confidence interval, 1.24 to 2.16; Ptrend,0.001). In conclusion, higher baseline serum endothelin-1 levels associated with incident CKD and all-cause mortality during follow-up in this general population sample of blacks.
AB - Endothelin-1, a marker of endothelial dysfunction, is a potent vasoconstrictor released by endothelial cells and an important regulator of renal physiology. It is not known whether elevated serum levels of endothelin- 1 indicate future risk of kidney disease in the general population. In participants in the JacksonHeart Study, a community-based observational study of cardiovascular risk in black adults, we measured serum endothelin-1 level at baseline (2000-2004; n=3538). We defined incident CKD as EGFR,60 ml/min per 1.73 m2 and $30% EGFR decline at the third visit (2009-2013) relative to baseline among those participants with baseline EGFR $60 ml/min per 1.73 m2. At baseline, mean age was 55 years old, 37% of participants were men, and mean EGFR was 94 ml/min per 1.73 m2. Over a median follow-up of 8 years, 228 (6.4%) cases of incident CKD occurred in participants. Participants with baseline endothelin-1 levels in higher quartiles had a greater incidence ofCKDin the fully adjustedmodel (odds ratio for fourth versus first quartile, 1.81; 95% confidence interval, 1.11 to 2.96; Ptrend=0.04). Endothelin-1 positively associated with all-cause mortality (hazard ratio for fourth versus first quartile, 1.64; 95% confidence interval, 1.24 to 2.16; Ptrend,0.001). In conclusion, higher baseline serum endothelin-1 levels associated with incident CKD and all-cause mortality during follow-up in this general population sample of blacks.
UR - http://www.scopus.com/inward/record.url?scp=85032636341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032636341&partnerID=8YFLogxK
U2 - 10.1681/asn.2016111236
DO - 10.1681/asn.2016111236
M3 - Article
C2 - 28698270
AN - SCOPUS:85032636341
SN - 1046-6673
VL - 28
SP - 3337
EP - 3344
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 11
ER -